Protocol Ledger

NCT06439082 · Phase III · RECRUITING

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Interventional Phase III clinical trial protocol NCT06439082 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-24 Enrollment: 354 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06439082
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)354 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06439082
Protocol FieldVerified Registry Value
NCT IdentifierNCT06439082
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment354 participants (ESTIMATED)
Registered Start Date2024-10-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06439082
Hospital Research SiteLocationSite Profile
Johns Hopkins Hospital and Kimmel Cancer CenterBaltimore, MDOpen Hospital Dossier ->
East Carolina UniversityGreenville, NCOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI